Contents
Alaska is home to many reputable clinical research facilities, like Alaska Clinical Research Center, LLC, and Alaska Cancer Research & Education Center.
State experts collaborate to conduct culturally responsive and efficient health research to address the unique needs of every patient. All research projects are overseen by independent committees that make sure every aspect of the study produces flawless results.
Clinical Trials For Disease Areas in Alaska
Experts in Alaska take part in a wide range of clinical research areas. They study arctic medicine, traditional healing practices, health disparities, infectious diseases, mental health, and the effects of environmental factors on health.
Some clinical research trials in Alaska test new experimental treatments for cancer. While others take a more comprehensive look at already approved medications and their effect on different patients.
A recent report by the Alaska Native Tribal Health Consortium showed that Alaska Natives have the world’s highest known rate of one specific cancer – colorectal cancer. This report includes more than 50 years of data that can ultimately help assess long-term cancer trends and save lives.
Want to take part in clinical and academic research? Here is a list of upcoming and ongoing trials that can help.
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Not set, Anchorage, Alaska
Not set, Anchorage, Alaska
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Recruiting
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. Read Less
Gender:
ALL
Ages:
30 years and below
Trial Updated:
04/14/2025
Locations: Providence Alaska Medical Center, Anchorage, Alaska
Providence Alaska Medical Center, Anchorage, Alaska
Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Recruiting
This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical N-803 plus BCG versus BCG alone, in BCG naïve patients with high-grade NMIBC.
This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical N-803 plus BCG versus BCG alone, in BCG naïve patients with high-grade NMIBC. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Alaska Clinical Research Center, Anchorage, Alaska
Alaska Clinical Research Center, Anchorage, Alaska
Conditions: Non-muscle Invasive Bladder Cancer
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +9 locations
Anchorage Associates in Radiation Medicine, Anchorage, Alaska
Anchorage Radiation Therapy Center, Anchorage, Alaska
Alaska Breast Care and Surgery LLC, Anchorage, Alaska
Alaska Oncology and Hematology LLC, Anchorage, Alaska
Alaska Regional Hospital, Anchorage, Alaska
Alaska Women's Cancer Care, Anchorage, Alaska
Anchorage Oncology Centre, Anchorage, Alaska
Katmai Oncology Group, Anchorage, Alaska
Providence Alaska Medical Center, Anchorage, Alaska
Fairbanks Memorial Hospital, Fairbanks, Alaska
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Project: Every Child for Younger Patients With Cancer
Recruiting
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care. Read Less
Gender:
ALL
Ages:
25 years and below
Trial Updated:
08/08/2025
Locations: Providence Alaska Medical Center, Anchorage, Alaska
Providence Alaska Medical Center, Anchorage, Alaska
Conditions: Central Nervous System Neoplasm, Childhood Immature Teratoma, Childhood Langerhans Cell Histiocytosis, Childhood Mature Teratoma, Congenital Mesoblastic Nephroma, Lymphoproliferative Disorder, Myeloproliferative Neoplasm, Stromal Neoplasm, Carcinoma In Situ, Malignant Solid Neoplasm, Desmoid Fibromatosis, Ganglioneuroma, Melanocytic Neoplasm, Neuroendocrine Neoplasm, Adrenal Gland Pheochromocytoma, Malignant Neoplasm, Neoplasm of Uncertain Malignant Potential, Childhood Kidney Neoplasm
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Recruiting
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +7 locations
Anchorage Associates in Radiation Medicine, Anchorage, Alaska
Anchorage Radiation Therapy Center, Anchorage, Alaska
Alaska Breast Care and Surgery LLC, Anchorage, Alaska
Alaska Oncology and Hematology LLC, Anchorage, Alaska
Alaska Women's Cancer Care, Anchorage, Alaska
Anchorage Oncology Centre, Anchorage, Alaska
Katmai Oncology Group, Anchorage, Alaska
Providence Alaska Medical Center, Anchorage, Alaska
Conditions: Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Recruiting
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet kno... Read More
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known if radiation therapy is more effective with or without cisplatin in treating patients with squamous cell carcinoma of the head and neck. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +7 locations
Anchorage Associates in Radiation Medicine, Anchorage, Alaska
Anchorage Radiation Therapy Center, Anchorage, Alaska
Alaska Breast Care and Surgery LLC, Anchorage, Alaska
Alaska Oncology and Hematology LLC, Anchorage, Alaska
Alaska Women's Cancer Care, Anchorage, Alaska
Anchorage Oncology Centre, Anchorage, Alaska
Katmai Oncology Group, Anchorage, Alaska
Providence Alaska Medical Center, Anchorage, Alaska
Conditions: Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant, Lip and Oral Cavity Squamous Cell Carcinoma, p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oral Cavity Verrucous Carcinoma, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Recruiting
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period. Read Less
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Site US10052, Anchorage, Alaska
Site US10052, Anchorage, Alaska
Conditions: Prostate Cancer
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Recruiting
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them. Read Less
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
08/08/2025
Locations: Providence Alaska Medical Center, Anchorage, Alaska
Providence Alaska Medical Center, Anchorage, Alaska
Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Providence Alaska Medical Center, Anchorage, Alaska
Providence Alaska Medical Center, Anchorage, Alaska
Conditions: Breast Cancer
Paid Clinical Trials in Alaska
Paid clinical trials in Alaska help doctors find better treatments and answer specific scientific questions that can improve patient care. These trials provide ways how to treat, detect, and prevent various diseases.
With AK paid clinical trials, volunteers get compensation for their contribution. Compensation comes in the form of monetary and non-monetary gain.
Clinical Trials For Health Volunteers in Alaska
Research teams in Alaska owe much of their success to health volunteers who selflessly dedicate their time and energy to provide valuable data. Volunteers are the heart and soul of Alaska’s research community.
With their contribution, experts can learn more about the state’s environment, health, and culture, and create innovative solutions that can benefit everyone involved.
Here is a list of trials that can help you make a change.
No trials could be found at this time
Medical Discoveries and Innovation in Alaska
Alaska clinical research has long pushed the boundaries of healthcare and improved the well-being of its diverse population. Many of today’s innovations and discoveries come from the state. Here is a list of some of the most impactful discoveries.
- Indigenous Research Program: The Alaska Indigenous Research Program (AKIRP) allowed experts to incorporate traditional healing practices into modern medicine. This innovative approach helps tailor current medical treatment to the patient’s needs.
- Wildlife-Transmitted Disease Studies: Alaska’s unique ecosystem has provided a natural laboratory for the study of diseases transmitted by wildlife. These include conditions like Lyme disease and hantavirus. Research in this area has helped us better understand zoonotic diseases and how to prevent them.
- Genomic Research in Rare Population: Alaska’s remote and genetically distinct populations have been the focus of genetic research. The data collected helped study rare diseases and genetic variations that can benefit medical treatment.
Why Alaska Is A Great Place For Clinical Research
Alaska is the perfect location for measuring disparities in care. Here 59.3% of the population is White, 14.9% is American Indian, 7.5% is Hispanic, 7.1% is Multiracial, 6.4% is Asian, 3.2% is Black, and 1.6% is Native Hawaiian.